Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Long Acting Contraception Market

ID: MRFR/HC/31158-HCR
128 Pages
Rahul Gotadki
Last Updated: April 24, 2026

Long Acting Contraception Market Research Report By Method of Contraception (Implants, Intrauterine Devices, Injectables, Pills), By Delivery Mode (Subdermal, Intrauterine, Intramuscular), By Demographics (Age Group, Socioeconomic Status, Marital Status), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Long Acting Contraception Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Method of Contraception (USD Billion) | |
      1. 4.1.1 Implants | |
      2. 4.1.2 Intrauterine Devices | |
      3. 4.1.3 Injectables | |
      4. 4.1.4 Pills |
    2. 4.2 Healthcare, BY Delivery Mode (USD Billion) | |
      1. 4.2.1 Subdermal | |
      2. 4.2.2 Intrauterine | |
      3. 4.2.3 Intramuscular |
    3. 4.3 Healthcare, BY Demographics (USD Billion) | |
      1. 4.3.1 Age Group | |
      2. 4.3.2 Socioeconomic Status | |
      3. 4.3.3 Marital Status |
    4. 4.4 Healthcare, BY Distribution Channel (USD Billion) | |
      1. 4.4.1 Hospital Pharmacies | |
      2. 4.4.2 Retail Pharmacies | |
      3. 4.4.3 Online Pharmacies |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Bayer (DE) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Merck & Co. (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Allergan (IE) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 HRA Pharma (FR) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Mylan (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Pfizer (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Bristol-Myers Squibb (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    7. 6.4 US MARKET ANALYSIS BY DELIVERY MODE |
    8. 6.5 US MARKET ANALYSIS BY DEMOGRAPHICS |
    9. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    10. 6.7 CANADA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    11. 6.8 CANADA MARKET ANALYSIS BY DELIVERY MODE |
    12. 6.9 CANADA MARKET ANALYSIS BY DEMOGRAPHICS |
    13. 6.10 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    16. 6.13 GERMANY MARKET ANALYSIS BY DELIVERY MODE |
    17. 6.14 GERMANY MARKET ANALYSIS BY DEMOGRAPHICS |
    18. 6.15 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    19. 6.16 UK MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    20. 6.17 UK MARKET ANALYSIS BY DELIVERY MODE |
    21. 6.18 UK MARKET ANALYSIS BY DEMOGRAPHICS |
    22. 6.19 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    23. 6.20 FRANCE MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    24. 6.21 FRANCE MARKET ANALYSIS BY DELIVERY MODE |
    25. 6.22 FRANCE MARKET ANALYSIS BY DEMOGRAPHICS |
    26. 6.23 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    27. 6.24 RUSSIA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    28. 6.25 RUSSIA MARKET ANALYSIS BY DELIVERY MODE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY DEMOGRAPHICS |
    30. 6.27 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    31. 6.28 ITALY MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    32. 6.29 ITALY MARKET ANALYSIS BY DELIVERY MODE |
    33. 6.30 ITALY MARKET ANALYSIS BY DEMOGRAPHICS |
    34. 6.31 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    35. 6.32 SPAIN MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    36. 6.33 SPAIN MARKET ANALYSIS BY DELIVERY MODE |
    37. 6.34 SPAIN MARKET ANALYSIS BY DEMOGRAPHICS |
    38. 6.35 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DELIVERY MODE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY DEMOGRAPHICS |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    45. 6.42 CHINA MARKET ANALYSIS BY DELIVERY MODE |
    46. 6.43 CHINA MARKET ANALYSIS BY DEMOGRAPHICS |
    47. 6.44 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    48. 6.45 INDIA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    49. 6.46 INDIA MARKET ANALYSIS BY DELIVERY MODE |
    50. 6.47 INDIA MARKET ANALYSIS BY DEMOGRAPHICS |
    51. 6.48 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    52. 6.49 JAPAN MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    53. 6.50 JAPAN MARKET ANALYSIS BY DELIVERY MODE |
    54. 6.51 JAPAN MARKET ANALYSIS BY DEMOGRAPHICS |
    55. 6.52 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DELIVERY MODE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY DEMOGRAPHICS |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY DELIVERY MODE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY DEMOGRAPHICS |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    64. 6.61 THAILAND MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    65. 6.62 THAILAND MARKET ANALYSIS BY DELIVERY MODE |
    66. 6.63 THAILAND MARKET ANALYSIS BY DEMOGRAPHICS |
    67. 6.64 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    68. 6.65 INDONESIA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    69. 6.66 INDONESIA MARKET ANALYSIS BY DELIVERY MODE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY DEMOGRAPHICS |
    71. 6.68 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY DELIVERY MODE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY DEMOGRAPHICS |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    78. 6.75 BRAZIL MARKET ANALYSIS BY DELIVERY MODE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY DEMOGRAPHICS |
    80. 6.77 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    81. 6.78 MEXICO MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    82. 6.79 MEXICO MARKET ANALYSIS BY DELIVERY MODE |
    83. 6.80 MEXICO MARKET ANALYSIS BY DEMOGRAPHICS |
    84. 6.81 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY DELIVERY MODE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY DEMOGRAPHICS |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY MODE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DEMOGRAPHICS |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY MODE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DEMOGRAPHICS |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY MODE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DEMOGRAPHICS |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY METHOD OF CONTRACEPTION |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY DELIVERY MODE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY DEMOGRAPHICS |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY METHOD OF CONTRACEPTION, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY METHOD OF CONTRACEPTION, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY DELIVERY MODE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY DELIVERY MODE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY DEMOGRAPHICS, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY DEMOGRAPHICS, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY METHOD OF CONTRACEPTION, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY DELIVERY MODE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Method of Contraception (USD Billion, 2025-2035)

  • Implants
  • Intrauterine Devices
  • Injectables
  • Pills

Healthcare By Delivery Mode (USD Billion, 2025-2035)

  • Subdermal
  • Intrauterine
  • Intramuscular

Healthcare By Demographics (USD Billion, 2025-2035)

  • Age Group
  • Socioeconomic Status
  • Marital Status

Healthcare By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions